source
- Eli Lilly inks $3.35 B China partnership as Immunovant halts lupus drug trialEli Lilly announced a new alliance with Beijing‑based InnoCare Pharma that could be worth up to $3.35 billion. The deal includes an upfront payment of $100 million and up to five target programs fo…
- Kyverna reports durable responses in early cell therapy trial for autoimmune diseaseKyverna Therapeutics announced new data from its cell therapy candidate targeting an autoimmune condition, marking progress toward a potential first‑in‑class product. The results showed that a not…